Aventis Insuman Fourth Quarter NDA Planned After Manufacturing Changes
Executive Summary
Aventis Pharma is targeting a fourth quarter NDA filing for its Insuman recombinant human insulin family after undergoing some changes in the manufacturing process of the compound.
You may also be interested in...
Aventis Lantus Phase IIIb Trial To Compare Nocturnal Hypoglycemia Rates
Aventis is conducting a Phase IIIb trial to compare the incidence of nocturnal hypoglycemia with its insulin glargine product Lantus and NPH human insulin (Lilly's Humulin or Novo Nordisk's Novolin) in patients with type 2 diabetes.
Aventis Lantus Phase IIIb Trial To Compare Nocturnal Hypoglycemia Rates
Aventis is conducting a Phase IIIb trial to compare the incidence of nocturnal hypoglycemia with its insulin glargine product Lantus and NPH human insulin (Lilly's Humulin or Novo Nordisk's Novolin) in patients with type 2 diabetes.
Hoechst Marion Roussel Amaryl Sales Reach $62 Mil. In Second Quarter
Worldwide sales of Hoechst Marion Roussel's Amaryl sulfonylurea treatment for type 2 diabetes increased by 77% in the second quarter to $62 mil. (EURO 58 mil.), the company reported in an Aug. 4 statement on financial results.